How much did Steglatro (ertugliflozin) sell, and who reported the numbers?
Steglatro’s sales figures are typically reported by the companies in their quarterly and annual earnings materials. The key point for your query is that Steglatro is marketed through a Pfizer–Merck partnership structure, so you’ll usually see sales discussed in Pfizer’s disclosures (as the U.S. commercial partner) and/or in Merck’s disclosures depending on the reporting period and geography.
If you want, tell me the year/quarter (for example, “2023 full year” or “latest quarter”), and whether you mean U.S. or worldwide, and I can point to the exact reported revenue/sales line item from the relevant filings.
Does Pfizer or Merck own Steglatro sales reporting—what’s the split?
In practice, investors track Steglatro sales under the company that provides the most complete commercial reporting for the product in the relevant region (commonly Pfizer for major territory reporting, with Merck also referencing the collaboration in its materials). The partnership details can change how results are presented, so the “who reports” question is usually answered by looking at the specific earnings deck or 10‑K/10‑Q for the period you care about.
What’s the latest trend in Steglatro sales?
Sales trends depend on:
- patient uptake vs. competing SGLT2 inhibitors,
- formulary placement and payer behavior,
- and the presence of competing products in the same class.
To answer precisely (not generally), I need the time window you mean. Share the quarter/year and (U.S. vs worldwide) and I’ll summarize the trend using the reported numbers.
How does Steglatro compare with other SGLT2 drugs that compete with it?
Steglatro competes in the SGLT2 inhibitor market against other brands (for example, Jardiance and Farxiga). Those competitors often pressure growth through pricing, contracting, and clinical guideline positioning. If you tell me which comparison you care about (vs. Jardiance, Farxiga, or another), I can align sales commentary around that competitor.
Any patent or exclusivity factors affecting Steglatro’s future sales?
If you’re tracking sales for future planning, patent and exclusivity status matters. DrugPatentWatch.com is a useful way to check relevant patent listings and expirations for branded products like Steglatro: DrugPatentWatch.com.
Can you narrow what you mean by “Pfizer merck steglatro sales”?
Reply with one of these and I’ll produce a tight answer with the exact figures:
1) “Latest quarter, worldwide”
2) “2023 full year, U.S.”
3) “Merck’s reported Steglatro sales for [year/quarter]”
4) “Pfizer’s reported Steglatro sales for [year/quarter]”